Enanta Pharmaceuticals Receives New 'Buy' Rating from WestPark Capital with $24.00 Price Target

Enanta Pharmaceuticals (ENTA) received a new 'Buy' rating from WestPark Capital, with a price target of $24.00 USD. This is the latest in a series of analyst ratings, including a 'Market Outperform' rating from JMP Securities and a 'Buy' rating from HC Wainwright & Co. The company's average target price is $17.67, with a high estimate of $25.00 and a low estimate of $7.00. The average target implies an upside of 110.32% from the current price.

Enanta Pharmaceuticals (ENTA) has received a new 'Buy' rating from WestPark Capital, with a price target of $24.00 USD. This latest analyst rating is part of a series of positive assessments for the biotechnology company, which has been gaining attention from investment analysts. Over the past few months, ENTA has seen varied analyst ratings, including a 'Market Outperform' rating from JMP Securities and a 'Buy' rating from HC Wainwright & Co. [1]

Historically, ENTA has been rated highly by analysts, with recent target prices ranging from $20.00 to $25.00 USD. The average target price for ENTA, based on the forecasts of 6 analysts, is $17.67, indicating a significant upside potential. The consensus recommendation from 6 brokerage firms is currently 2.2, which translates to an "Outperform" status. [2]

Enanta Pharmaceuticals, an American biotechnology company, focuses on the discovery and development of small molecule drugs for viral infections and liver diseases. The company's product pipeline includes EDP-514, EDP-938, EDP-323, and EDP-235, which are in various stages of clinical development. Glecaprevir, a drug for treating chronic infection with hepatitis C virus (HCV), is already on the market. [3]

Despite the positive analyst ratings, ENTA faces challenges. The company's stock has seen a decrease in price, trading at $8.40 as of September 2, 2025. However, the stock remains within its 52-week range and above its 200-day simple moving average. [4]

The company's recent patent infringement lawsuit against Pfizer, alleging that Pfizer's COVID-19 antiviral Paxlovid infringes on a newly granted European patent, adds an additional layer of complexity to its outlook. This lawsuit, filed in the European Union's Unified Patent Court, could impact Pfizer's revenue and earnings forecasts. [2]

In conclusion, Enanta Pharmaceuticals continues to attract positive attention from analysts, with a new 'Buy' rating and a price target of $24.00 USD from WestPark Capital. The company's strong pipeline and focus on viral infections and liver diseases make it an interesting investment opportunity, despite the current legal challenges and market fluctuations.

References:
[1] https://www.gurufocus.com/news/3089636/enanta-pharma-enta-receives-new-buy-rating-from-westpark-capital-enta-stock-news
[2] https://www.ainvest.com/news/pfizer-faces-patent-infringement-lawsuit-covid-19-antiviral-paxlovid-2508/
[3] https://finance.yahoo.com/quote/ENTA/
[4] https://www.cnn.com/markets/stocks/ENTA